Provides relative to healthcare providers displaying evidence of proper licensure in advertising (EN NO IMPACT See Note)
Summary
HB 423 amends Louisiana law in two main areas. First, it strengthens a rule governing opioid prescriptions for chronic pain by prohibiting insurers from denying a medically necessary opioid prescription written by a licensed physician and substituting a different medication when the prescribed drug has abuse-deterrent properties and the proposed substitute does not. Second, it revises the state’s advertising law for the use of the title “Doctor” or “Dr.” by healthcare providers, tying violations to enforcement under the Unfair Trade Practices and Consumer Protection Law and to any applicable licensing-board rules.
The bill is aimed at both patient access and professional transparency. On the prescription side, it protects physician-prescribed opioid medications from insurer-driven substitution in a narrow set of circumstances. On the advertising side, it is intended to require healthcare professionals to display evidence of proper licensure in person or in advertisements, and it clarifies how violations can be enforced. The enrolled bill also includes technical corrections and related conforming changes to existing statutes.
Impact
HB 423 amends R.S. 22:1060.7 and R.S. 51:413, affecting insurers, physicians, and other healthcare professionals who use professional titles in advertising. It limits insurer substitution practices for certain opioid prescriptions with abuse-deterrent properties and makes violations of the “Doctor”/“Dr.” advertising rules enforceable under the Unfair Trade Practices and Consumer Protection Law, in addition to licensing-board discipline. The bill therefore expands consumer-protection style enforcement while preserving physician authority in a specific prescription context.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It passed the House 97-0, the Senate 38-0, and the House again 94-0 on concurrence, indicating strong agreement across chambers. The available record shows no committee transcript debate, suggesting the measure was relatively noncontroversial or narrowly focused.
Contention
No major points of contention are reflected in the available materials. The only potentially sensitive issues are the limits placed on insurer substitution of opioid medications and the enforcement of advertising/licensure requirements for healthcare providers. Even so, the unanimous votes suggest those issues did not generate significant opposition in the legislative process.